News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Isotechnika Pharma Inc. (ISA.TO) Receives Additional Funding From the Government of Canada for the Preclinical Development of NICAM 440-02 as an Anti-Hepatitis C Agent



6/18/2013 8:55:39 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EDMONTON, Alberta, June 18, 2013 (GLOBE NEWSWIRE) -- Isotechnika Pharma Inc. (TSX:ISA) ("Isotechnika" or the "Company") today announced that it has received additional funding from the National Research Council Industrial Research Assistance Program ("NRC-IRAP") for its Non-Immunosuppressive Cyclophilin Antagonist Molecules ("NICAMs") program.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES